From the Food and Drug Administration |

Risk of Drug Interactions With St John's Wort

Jane E. Henney, MD
JAMA. 2000;283(13):1679. doi:10.1001/jama.283.13.1679.
Text Size: A A A
Published online


The FDA has asked health care professionals to caution patients about the risk of potentially significant interaction between St John's wort (Hypericum perforatum), an herbal product marketed as a dietary supplement, and other drugs, including indinavir, a protease inhibitor (PI) used for HIV infection.

The agency's warning is based on a study conducted by the National Institutes of Health with eight healthy, HIV-negative volunteers. Participants received 800 mg of indinavir administered on an empty stomach every 8 hours for 4 doses, with serial pharmacokinetic sampling before and after the fourth dose. For the next 14 days, volunteers took 300 mg of St John's wort (0.3% hypericin) three times daily with food. On the last day of St John's wort, volunteers again received took 800 mg of indinavir every four hours for a total of 4 doses, with pharmacokinetic sampling before and for 5 hours serially after the fourth dose.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Synergy and other interactions in phytomedicines. Phytomedicine 2001;8(5):401-9.

The Rational Clinical Examination
Cross-Reactivity With Other -Lactam Antibiotics